Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 162

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 162
---
thanolamines and uses thereof is a patent family filed on February 10, 2023, as part of our cooperation agreement with SciSparc. The patent application relates to compositions and methods for potentiating therapeutic effects and/or reducing side-effects of N,N-dimethyltryptamine. The patent application provides pharmaceutical compositions and combinations comprising N,N-dimethyltryptamine and N-acylethanolamines for example, Palmitoylethanolamide (PEA) and methods for their use in a variety of indications amenable to treatment with N,Ndimethyltryptamine, including, but not limited to cerebral ischemia and hypoxia. Compositions comprising 5-METHOXY-2-AMINOINDAN for treatment of depression is a patent family filed on March 29, 2023. The patent application relates to compositions and methods for treatment of depression. The patent application provides pharmaceutical compositions comprising 5-methoxy-2-aminoindan (“MEAI”) and methods for their use in treatment of depression. COMPOSITIONS AND METHODS FOR TREATING EATING DISORDERS is a pending provisional application directed to treating eating disorders with 3-MMC. If converted to a nonprovisional, the 20 year term for this family ends on March 20, 2045. 5-methoxy-2-aminoindan is a pending provisional application directed to methods for treating metabolic syndrome using 5-methoxy-2-aminoindan. If converted to a nonprovisional, the 20 year term for this family ends on July 8, 2045. With respect to the aforementioned provisional patent applications, we intend to decide whether to file non-provisional patent applications at some time before each application lapses (for each, within one year of their filing date). We intend to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. License Agreements On January 15, 2024, we entered into a license agreement with BIRAD, the research and development company of Bar-Ilan University, which provides us with an exclusive, perpetual, worldwide and sublicensable license to use the joint patent that we have with BIRAD to further develop, manufacture and commercialize products for innovative treatment of cocaine addiction (“the BIRAD License Agreement”). According to the BIRAD License Agreement, we shall pay BIRAD royalties at the rate of 1.